Tilray | TRLY - 销售收入

股票价格

7.72

每天变化

-0.15 -1.91%

每月一次

-17.26%

每年

1,165.57%

Q2 预测

8.21

金融业

USD

USD 2.1B

现金及等价物

USD 264.83M

USD 164.37M

USD 729.32M

USD 259.32M

USD 640.95M

USD -20.01M

USD 8.37M

USD 2.84K

EPS每股收益

USD -0.41

股本和储备

USD 1.58B

USD 57.47M

债务利息支出

USD 6.7M

USD 12.83M

USD 268.59M

USD 6.03B

USD -44.93M

USD 237.52M

USD -20.01M

普通股股本

USD 116.52M

11.57

USD -39.96M

USD 217.51M

销售和管理费用

USD 24.85M

USD 282.79M

贸易债权人

USD 114.5M

应收帐款人

USD 109.07M

	销售	更改		日
Acasti Pharma	USD -4.76M		4.76M	2024-12
Akebia Therapeutics	USD 57.62M		1.14M	2025-12
Alaunos Therapeutics	USD 2K		2K	2025-03
Aurora Cannabis	CAD 94.19M		3.82M	2025-12
Avita Medical	AUD 17.61M		805K	2025-12
Canopy Growth	CAD 74.54M		7.86M	2025-12
Cronos Group	USD 58.39M		22.05M	2025-12
Dianthus Therapeutics	USD 284K		112K	2025-12
Divis Laboratories Ltd	INR 26.04B		1.11B	2025-12
Ionis Pharmaceuticals	USD 246M		43M	2026-03
IQVIA Holdings	USD 4.15B		210M	2026-03
Knight Therapeutics	CAD 133.11M		11.56M	2025-12
Moderna	USD 389M		289M	2026-03
Organigram Holdings	CAD 63.54M		16.52M	2025-12
Organon & Co	USD 1.46B		50M	2026-03
Revvity	USD 711M		61.06M	2026-03
Tectonic Therapeutic	USD 0		0	2024-12
Tilray	USD 217.51M		74.75M	2025-12
Viatris	USD 3.52B		180M	2026-03
Xeris Pharmaceuticals	USD 83.13M		2.68M	2026-03
Zealand Pharma A/S	68.91M		19.35M	2025-12